Servicios Personalizados
Revista
Articulo
Español (pdf)
Artículo en XML
Referencias del artículo
Traducción automática
Enviar artículo por emailIndicadores
Citado por SciELO 
Accesos
Links relacionados
Similares en
SciELO
Compartir
Permalink
Revista alergia México
versión On-line ISSN 2448-9190
Resumen
AGUILAR HINOJOSA, Nadia Karina y FIGUEROA SAAVEDRA, Evelyn Itzamara. Desensitization to deferasirox in a patient with hemochromatosis. Case report. Rev. alerg. Méx. [online]. 2023, vol.70, n.3, pp.159-162. Epub 29-Sep-2023. ISSN 2448-9190. https://doi.org/10.29262/ram.v70i3.1256.
Background:
Deferasirox is an active iron chelator, used in the treatment of iron overload such as hemochromatosis. Up to 28% may present adverse reactions to said drug. A desensitization protocol for this drug may be useful when there are no other therapeutic options.
Case report:
A 52-year-old female with a diagnosis of hemochromatosis who began treatment with phlebotomy, poor response and tolerance, so it was decided to treat with deferasirox 500 mg daily, presenting symptoms of urticaria and angioedema on the third dose. Hospitalization was decided for a desensitization protocol with an initial dose of 0.6mg with a gradual increase in the dose, reaching a maintenance dose of 500 mg per day on the third day.
Conclusion:
The rapid desensitization protocol for Deferasirox is useful when there is no response or therapeutic alternative.
Palabras llave : Deferasirox; Hemochromatosis; Desensitization; Allergy.
